Novartis recall
Novartis is voluntarily recalling five lots of GenTeal eye gel and two lots of GenTeal gel drops, the firm announces Nov. 16. The recall is a result of concerns regarding product sterility in both products. Novartis found the presence of mold in "a small number of samples" of the eye gel which may cause infection in susceptible people, particularly those with compromised immune systems, the company states. The sterility of the gel drops also was contested due to a risk of potential contamination. Consumers who may have purchased the products should contact Novartis, the company states...
More from Archive
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.
With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.